ClinicalTrials.gg
CompletedNCT01339559BRITE™Updated Aug 17, 2021Results posted

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB BIOSCIENCES, Inc.. Completed at 184 sites in 28 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
767
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
3rd of 34
767 · median 94
Started
2011
with 3 others
Phase 3
21 of 34
1 open now
Registered
16th of 34
by date
Lead sponsor
1 of 34
UCB BIOSCIENCES, Inc.

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 21 in phase 3, and was the 16th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This is a Phase 3, open label, long term follow-up (LTFU), multicenter, noncomparative, and single arm study of brivaracetam (BRV).

Read the detailed description

The primary objective is to evaluate the long term safety and tolerability of BRV at individualized doses up to a maximum of 200 mg/day in epilepsy subjects.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Partial Onset Seizures
  • Adjunctive treatment
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject completed the Treatment Period of N01358 or the evaluation period of N01258
  • Male/female subject from 16 years or older. Subject under 18 years may only be included where legally permitted and ethically accepted
  • Subject for whom the Investigator believes a reasonable benefit from the long term administration of BRV may be expected
  • Female subject without (premenarcheal, for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible

Exclusion criteria

Exclusion Criteria:

  • Subject has developed to any components of the medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core studies
  • Severe medical, neurological, or psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
  • Poor compliance with the visit schedule or medication intake in the previous BRV study
  • Planned participation in any other clinical study of another investigational drug or device during this study
  • Pregnant or lactating woman
  • Any medical condition which, in the Investigator's opinion, warrants exclusion
  • Subject has a lifetime history of suicide attempt or has suicidal ideation in the past 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
767 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Brivaracetam with a maximum of 200 mg/day

    Drug: Brivaracetam

Interventions

  • Tablet, Flexible dosing up to 200 mg/day, twice daily. The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor.

    Also known as: UCB34714

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

    Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.

    Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)

  2. Percentage of Participants Who Withdrew Due to Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.

    Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)

  3. Percentage of Participants With at Least One Serious Adverse Event (SAE)

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is as infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Entry Visit (Month 0) until the Last Visit (up to 84 months)

Secondary outcomes

  1. Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

    The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.

    Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)

  2. Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

    The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.

    Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)

  3. Responder Rate in POS (Type I) Frequency Over the Evaluation Period

    A responder is defined as a subject with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.

    Time frame: From Baseline of the previous study until the Last Visit (up to 84 months)

07

Results

Posted Jun 4, 2020

Participant flow

The study started to enroll patients in May 2011 and concluded in April 2019. 767 participants were included in the Enrolled Set but 1 participant from the United States of America was lost to follow-up and was excluded from the Safety Analysis Set.

Participant flow — Overall Study
MilestoneBrivaracetam
Started766
Completed368
Not completed398
Withdrew: Adverse event92
Withdrew: Death5
Withdrew: Lack of efficacy164
Withdrew: Lost to follow-up22
Withdrew: Subject choice89
Withdrew: Protocol violation15
Withdrew: Study closure at site1
Withdrew: Incarcerated2
Withdrew: Epilepsy surgery1
Withdrew: Pregnancy planned2
Withdrew: Left the country1
Withdrew: Investigator decision2
Withdrew: Patient didn't wish to continue1
Withdrew: Pi decision1

Outcome measures

PrimaryPercentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)

Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.

Time frame:
From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)83.9
PrimaryPercentage of Participants Who Withdrew Due to Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or trial subject that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.

Time frame:
From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdrew Due to Adverse Events (AEs)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants Who Withdrew Due to Adverse Events (AEs)11.9
PrimaryPercentage of Participants With at Least One Serious Adverse Event (SAE)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is as infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Entry Visit (Month 0) until the Last Visit (up to 84 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Serious Adverse Event (SAE)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants With at Least One Serious Adverse Event (SAE)18.4
SecondaryPartial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28.

Time frame:
From Baseline of the previous study until the Last Visit (up to 84 months)
Reported as:
Median · Seizures per 28 days
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
Seizures per 28 daysBrivaracetam (POS Efficacy)
Baseline9.7 (5.5 to 23.7)
On Treatment4.2 (1.4 to 12.7)
SecondaryPercent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of percent change in POS frequency.

Time frame:
From Baseline of the previous study until the Last Visit (up to 84 months)
Reported as:
Median · Percent change
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
Percent changeBrivaracetam (POS Efficacy)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period52.0 (16.8 to 81.5)
SecondaryResponder Rate in POS (Type I) Frequency Over the Evaluation Period

A responder is defined as a subject with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Note: Since N01258 was a safety study, participants were not required to meet seizure frequency requirements during the Baseline Period, and the Baseline Period was short (ie, 7 days). Therefore, participants from N01258 were excluded from efficacy summaries in the variable of responder rates in POS frequency.

Time frame:
From Baseline of the previous study until the Last Visit (up to 84 months)
Reported as:
Number · Percentage of participants
Responder Rate in POS (Type I) Frequency Over the Evaluation Period
Percentage of participantsBrivaracetam (POS Efficacy)
Responder Rate in POS (Type I) Frequency Over the Evaluation Period51.7

Adverse events

Collected over From Entry Visit (Month 0) until the Last Visit (up to 84 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam (SS)5/766 (0.7%)140/766 (18.3%)421/766 (55%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventBrivaracetam (SS)
ConvulsionNervous system disorders15/766
Status epilepticusNervous system disorders11/766
EpilepsyNervous system disorders7/766
Suicide attemptPsychiatric disorders7/766
PneumoniaInfections and infestations5/766
Suicidal ideationPsychiatric disorders5/766
Seizure clusterNervous system disorders4/766
CholelithiasisHepatobiliary disorders3/766
Toxicity to various agentsInjury, poisoning and procedural complications3/766
HyponatraemiaMetabolism and nutrition disorders3/766
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBrivaracetam (SS)
HeadacheNervous system disorders102/766
DizzinessNervous system disorders100/766
SomnolenceNervous system disorders73/766
NasopharyngitisInfections and infestations65/766
FatigueGeneral disorders59/766
Upper respiratory tract infectionInfections and infestations59/766
Urinary tract infectionInfections and infestations57/766
Back painMusculoskeletal and connective tissue disorders46/766
DepressionPsychiatric disorders45/766
ContusionInjury, poisoning and procedural complications44/766

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all participants who took at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years19
Between 18 and 65 years722
>=65 years25
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean40.0 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female396
Male370
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
White561
African-American37
Asian85
Other77
Missing6
08

Study locations

184 sites
  • 001
    Phoenix, Arizona 85004, United States
  • 013
    Phoenix, Arizona 85006, United States
  • 006
    Tucson, Arizona 85718, United States
  • 775
    Little Rock, Arkansas 72205, United States
  • 025
    San Francisco, California 94115, United States
  • 060
    Aurora, Colorado 80045, United States
  • 071
    Miami, Florida 33176, United States
  • 027
    Orlando, Florida 32819, United States
  • 064
    Port Charlotte, Florida 33952, United States
  • 023
    Atlanta, Georgia 30322, United States
  • 048
    Rome, Georgia 30165, United States
  • 039
    Boise, Idaho 83702, United States
  • 029
    Chicago, Illinois 60612, United States
  • 005
    Peoria, Illinois 61637, United States
  • 017
    Winfield, Illinois 60190, United States
  • 020
    Ames, Iowa 50010, United States
  • 069
    Iowa City, Iowa 52242, United States
  • 780
    Lexington, Kentucky 40536, United States
  • 008
    Bethesda, Maryland 20817, United States
  • 068
    Waldorf, Maryland 20603, United States
  • 009
    Golden Valley, Minnesota 55422, United States
  • 032
    Lebanon, New Hampshire 03756, United States
  • 042
    Hamilton, New Jersey 08619, United States
  • 099
    New York, New York 10011, United States
  • 022
    New York, New York 10016, United States
  • 098
    Poughkeepsie, New York 12601, United States
  • 010
    Asheville, North Carolina 28806, United States
  • 003
    Durham, North Carolina 27705, United States
  • 034
    Cleveland, Ohio 44195, United States
  • 778
    Columbus, Ohio 43210, United States
  • 070
    Columbus, Ohio 43215, United States
  • 002
    Toledo, Ohio 43614, United States
  • 043
    Oklahoma City, Oklahoma 73112, United States
  • 091
    Oklahoma City, Oklahoma 73112, United States
  • 054
    Tulsa, Oklahoma 74136-83, United States
  • 015
    Philadelphia, Pennsylvania 19107, United States
  • 028
    Charleston, South Carolina 29425, United States
  • 021
    Port Royal, South Carolina 29965, United States
  • 776
    Nashville, Tennessee 37232-25, United States
  • 061
    Austin, Texas 78758, United States
  • 011
    Dallas, Texas 75251, United States
  • 777
    Dallas, Texas 75251, United States
  • 035
    Dallas, Texas 75390, United States
  • 049
    Houston, Texas 77025, United States
  • 050
    Mansfield, Texas 76063, United States
  • 036
    Charlottesville, Virginia 22908, United States
  • 056
    Spokane, Washington 99204, United States
  • 052
    Madison, Wisconsin 53715, United States
  • 057
    Milwaukee, Wisconsin 53215, United States
  • 202
    Innsbruck, Austria
  • 201
    Linz, Austria
  • 203
    Wien, Austria
  • 226
    Hechtel-Eksel, Belgium
  • 227
    Leuven, Belgium
  • 104
    Belo Horizonte, Brazil
  • 100
    Florianopolis, Brazil
  • 101
    Sao Paulo, Brazil
  • 294
    Blagoevgrad, Bulgaria
  • 286
    Sofia, Bulgaria
  • 287
    Sofia, Bulgaria
  • 075
    Calgary, Alberta, Canada
  • 078
    London, Ontario, Canada
  • 076
    Toronto, Ontario, Canada
  • 077
    Greenfield Park, Quebec, Canada
  • 080
    Saskatoon, Saskatchewan, Canada
  • 079
    Montreal, Canada
  • 917
    Brno, Czechia
  • 916
    Kromeriz, Czechia
  • 913
    Ostrava Poruba, Czechia
  • 251
    Ostrava, Czechia
  • 256
    Ostrava, Czechia
  • 252
    Praha 1, Czechia
  • 253
    Praha 4, Czechia
  • 250
    Zlin, Czechia
  • 650
    Tallinn, Estonia
  • 652
    Tallinn, Estonia
  • 651
    Tartu, Estonia
  • 275
    Kuopio, Finland
  • 276
    Tampere, Finland
  • 301
    Bethune, France
  • 305
    Montpellier, France
  • 329
    Berlin, Germany
  • 326
    Bernau, Germany
  • 332
    Bielefeld, Germany
  • 902
    Erlangen, Germany
  • 331
    Göttingen, Germany
  • 327
    Kiel, Germany
  • 900
    Marburg, Germany
  • 335
    Muenchen, Germany
  • 334
    Osnabruck, Germany
  • 330
    Ravensburg, Germany
  • 328
    Ulm, Germany
  • 700
    Hong Kong, Hong Kong
  • 701
    Hong Kong, Hong Kong
  • 410
    Budapest, Hungary
  • 411
    Budapest, Hungary
  • 412
    Budapest, Hungary
  • 414
    Hajdú-Bihar, Hungary
  • 413
    Szekszard, Hungary
  • 731
    Nashik, Maharashtra, India

Showing the first 100 of 184 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗
  • Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212. Epub 2015 Oct 16. PubMed 26471380 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Apr 2019, 95 months.

Results were first posted in Jun 2020, 1 year 1 month after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 95 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2011
First posted
Apr 20, 2011
StartActual
May 11, 2011
Primary completionActual
Apr 18, 2019
CompletionActual
Apr 18, 2019
Results first posted
Jun 4, 2020
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01339559
Responsible party
Sponsor
First posted
Apr 20, 2011
Start date
May 11, 2011
Primary completion
Apr 18, 2019
Completion
Apr 18, 2019
Results posted
Jun 4, 2020
Last update
Aug 17, 2021

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion